Condition: Locally Advanced, Recurrent or Metastatic Malignancies · Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
This study was an open-label phase I study to evaluate the safety, tolerability, PK profile and potential efficacy of SSGJ-705 as a single agent in patients with advanced malignancies.
This description comes directly from the study's public registry record.
Jinming Yu, MD,Ph.D · +86-13806406293 · sdyujinming@126.com
Yuping Sun, MD,Ph.D · +86-13370582181 · 13370582181@163.com
Always discuss trial participation with your own doctor first.
| Affiliated Cancer Hospital of Shandong First Medical University | Jinan, Shandong, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06390774